{"id":"eca99ad0-d6db-401f-9575-6e22a77bfc14","companyId":"e401d2c7-b035-4dea-9b60-ae0d2bb9b99b","modelName":"Genesis RMN / GenesisX","slug":"stereotaxis-genesis","description":"Stereotaxis (NYSE American: STXS; headquartered in St. Louis, Missouri) pioneered Robotic Magnetic Navigation, a distinct surgical-robot modality in which two large external magnets robotically steer a magnetic-tipped catheter inside the heart for catheter-based electrophysiology and cardiac ablation. It is genuinely a robot, with computer-controlled physical actuation of an in-body instrument, but an unusual one whose manipulator is the magnetic field acting on a soft catheter rather than a rigid arm, placing it in a distinct endovascular sub-category rather than the soft-tissue laparoscopic mainstream. Its current-generation Genesis RMN system succeeded the legacy Niobe, the next-generation small-footprint GenesisX received its European CE mark in August 2024 and US FDA 510(k) clearance on November 10, 2025, and the MAGiC magnetic ablation catheter that the system steers received FDA approval on January 6, 2026, with the first US procedure performed at OHSU. The registry records it at commercial maturity, with more than 100 RMN systems installed across about 31 countries, public-company revenue, and GenesisX in early limited launch, and notes that the company signed an agreement to acquire the endovascular-robotics firm Robocath in early 2026. A correction to the dispatch framing: no Stereotaxis product named Mavericks exists in any primary source, and the real third leg of the portfolio is the MAGiC ablation catheter, so Mavericks is not recorded. The figure of more than 140,000 cumulative patients is a company marketing figure, and exact current GenesisX install counts beyond a first installation and limited launch are not verified.","formFactor":"surgical","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{"notes":[{"label":"Verified","value":"Stereotaxis (NYSE American: STXS; HQ St. Louis MO) pioneered Robotic Magnetic Navigation (RMN) for catheter-based electrophysiology: two external magnets reorient a magnetic-tipped catheter inside the heart. GenesisX got CE mark Aug 2024 + FDA 510(k) Nov 10 2025; the MAGiC ablation catheter got FDA approval Jan 6 2026 (first US procedure at OHSU). Signed an agreement to acquire Robocath (endovascular robotics, Q1 2026)."},{"label":"CORRECTION (dispatch framing)","value":"No Stereotaxis product named 'Mavericks' appears in any primary source. The real third leg of the current portfolio is the MAGiC ablation catheter (FDA Jan 2026); 'Mavericks' is a mis-recalled name and is NOT recorded."},{"label":"Modality + maturity","value":"It IS a robot (computer-controlled physical actuation of an in-body instrument), but an unusual one: the 'manipulator' is the magnetic field acting on a soft catheter, not a rigid arm. A distinct sub-category (endovascular/magnetic catheter robotics), not a soft-tissue laparoscopic robot. maturity=commercial (Genesis family long-commercialized; >100 RMN systems across ~31 countries; public-company revenue; GenesisX in early/limited launch)."},{"label":"Claimed but NOT verified","value":">140,000 cumulative patients (company/marketing figure); exact current GenesisX order/install count beyond 'first installation' + limited launch. Q1 2026 system revenue was small ($1.3M of $6.3M total), reflecting a mature/legacy installed base with GenesisX only beginning to ship."}],"products":"Genesis RMN (current-gen robotic magnetic navigation, FDA-cleared, succeeded legacy Niobe); GenesisX (next-gen small-footprint RMN, CE Aug 2024, FDA 510(k) Nov 10 2025); MAGiC magnetic ablation catheter (FDA approval Jan 6 2026); plus an imaging system. Niche: electrophysiology / cardiac ablation.","formFactor":"surgical (robotic magnetic navigation: robotically steers magnetic-tipped catheters inside the heart via external magnets)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.globenewswire.com/news-release/2025/11/10/stereotaxis-genesisx-fda-clearance","title":"Stereotaxis GenesisX RMN system receives US FDA 510(k) clearance (Nov 10 2025)","sourceName":"Stereotaxis (GlobeNewswire)"},{"url":"https://www.globenewswire.com/news-release/2026/01/06/stereotaxis-magic-catheter-fda","title":"Stereotaxis MAGiC magnetic ablation catheter receives FDA approval (Jan 6 2026)","sourceName":"Stereotaxis (GlobeNewswire)"},{"url":"https://www.globenewswire.com/news-release/2026/05/12/stereotaxis-q1-2026-results","title":"Stereotaxis Q1 2026 results (revenue $6.3M; Robocath acquisition agreement)","sourceName":"Stereotaxis (GlobeNewswire)"},{"url":"https://en.wikipedia.org/wiki/Stereotaxis","title":"Stereotaxis (NYSE American: STXS; robotic magnetic navigation; >100 RMN systems, ~31 countries)","sourceName":"Wikipedia"}],"aliases":["Stereotaxis Genesis","GenesisX","Genesis RMN","Niobe"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"createdAt":"2026-06-03T20:13:01.755Z","updatedAt":"2026-06-03T20:13:01.755Z","jsonLd":{"@context":"https://schema.org","@type":"Product","@id":"https://registry.deploy.report/models/stereotaxis-genesis","url":"https://registry.deploy.report/models/stereotaxis-genesis","name":"Genesis RMN / GenesisX","alternateName":["Stereotaxis Genesis","GenesisX","Genesis RMN","Niobe"],"description":"Stereotaxis (NYSE American: STXS; headquartered in St. Louis, Missouri) pioneered Robotic Magnetic Navigation, a distinct surgical-robot modality in which two large external magnets robotically steer a magnetic-tipped catheter inside the heart for catheter-based electrophysiology and cardiac ablation. It is genuinely a robot, with computer-controlled physical actuation of an in-body instrument, but an unusual one whose manipulator is the magnetic field acting on a soft catheter rather than a rigid arm, placing it in a distinct endovascular sub-category rather than the soft-tissue laparoscopic mainstream. Its current-generation Genesis RMN system succeeded the legacy Niobe, the next-generation small-footprint GenesisX received its European CE mark in August 2024 and US FDA 510(k) clearance on November 10, 2025, and the MAGiC magnetic ablation catheter that the system steers received FDA approval on January 6, 2026, with the first US procedure performed at OHSU. The registry records it at commercial maturity, with more than 100 RMN systems installed across about 31 countries, public-company revenue, and GenesisX in early limited launch, and notes that the company signed an agreement to acquire the endovascular-robotics firm Robocath in early 2026. A correction to the dispatch framing: no Stereotaxis product named Mavericks exists in any primary source, and the real third leg of the portfolio is the MAGiC ablation catheter, so Mavericks is not recorded. The figure of more than 140,000 cumulative patients is a company marketing figure, and exact current GenesisX install counts beyond a first installation and limited launch are not verified.","identifier":"eca99ad0-d6db-401f-9575-6e22a77bfc14","category":"surgical","publisher":{"@id":"https://deploy.report/#organization"}}}